ILOTYCIN GLUCEPTATE
Pre-Launcherythromycin gluceptate
NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILOTYCIN GLUCEPTATE is an injectable formulation of erythromycin gluceptate, a macrolide antibiotic administered intravenously. The product is in pre-launch stage and indicated for serious infections where oral or intramuscular administration is not feasible. It works by inhibiting bacterial protein synthesis via ribosomal binding.
Pre-Launch
Pre-launch stage indicates a lean commercial organization focused on regulatory clearance and market preparation activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ILOTYCIN GLUCEPTATE offers a unique pre-launch career opportunity focused on regulatory strategy, manufacturing scale-up, and market preparation. This role suits professionals seeking foundational product experience and ownership during the critical approval-to-launch transition phase.
Regulatory Affairs SpecialistManufacturing/Operations Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.